Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Targeting the uncommon alterations in CRC

Andrea Sartore-Bianchi • 9 Sep 2022
ESMO 2022
Colorectal Cancer Gastrointestinal Cancer Cetuximab Panitumumab

Andrea Sartore-Bianchi, MD, ASST Great Niguarda Metropolitan Hospital, Milan, discusses targeting uncommon alterations in colorectal cancer (CRC), including HER2 amplifications, KRASG12C mutations and alterations in NTRK, ALK and RET genes. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH

More from Andrea Sartore-Bianchi

1:17
The application of histology-agnostic treatments in metastatic colorectal cancer
Andrea Sartore-Bianchi • 9 Sep 2022
1:30
Overcoming acquired resistance to targeted therapy in colorectal cancer
Andrea Sartore-Bianchi • 9 Sep 2022
0:54
Targeted therapies in colorectal cancer
Andrea Sartore-Bianchi • 9 Sep 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals